Effect of acidosis on bilirubin-induced toxicity to human erythrocytes.
Unconjugated bilirubin binds to erythrocytes, eliciting crenation, lipid elution and hemolysis. The present work attempts to establish the role of acidosis on bilirubin-induced toxicity to human erythrocytes. To this end, pH values ranging from 7.0-8.0 were used to induce a different representation of acid and anionic bilirubin species, respectively. Erythrocytes from healthy donors were incubated with bilirubin and albumin (3:1, molar ratio), during 4 h. Erythrocyte-bound bilirubin was evaluated by albumin or chloroform extraction in an attempt to assess either mono- and dianion bilirubin adsorbed on the cell surface or colloidal aggregates, respectively. Cytotoxicity indicators, such as the morphological index, and the extent of phospholipids and hemoglobin release were also determined. The results showed that as pH drops from 8.0-7.0, less bilirubin is removed by albumin and more become recovered by chloroform. The data corroborate the predominance of anionic and non-aggregated bilirubin species at pH 8.0 with dimers and precipitates occurring at 7.0. In accordance, crenation and cell lysis were four times increased at acidic pH. In contrast, elution of phospholipids was 1.5 times less evident at the same pH, thus suggesting that formation of bilirubin complexes with membrane phospholipids may have contributed to prevent their release. In conclusion, both anionic and acid bilirubin species interact with human erythrocytes leading to cytotoxic alterations that may determine definitive lesions. Nevertheless, increased vulnerability to crenation and hemolysis are more likely to occur in acidic conditions pointing to the bilirubin precipitates as the main candidates of bilirubin-induced toxicity to erythrocytes.
Brito
Maria Alexandra
MA
Centro de Patogénese Molecular, Faculdade de Farmácia, University of Lisbon, Lisbon, Portugal. abrito@ff.ul.pt
Brites
Dora
D
D000138:Acidosis / Q000097:blood / Q000473:pathology*; D001663:Bilirubin / Q000633:toxicity*; D004912:Erythrocytes / Q000187:drug effects* / Q000473:pathology*; D006454:Hemoglobins / Q000378:metabolism; D006461:Hemolysis; D006801:Humans; D006863:Hydrogen-Ion Concentration; D050356:Lipid Metabolism; D010743:Phospholipids / Q000097:blood; D012709:Serum Albumin / Q000378:metabolism
D006454:Hemoglobins; D010743:Phospholipids; D012709:Serum Albumin; D001663:Bilirubin